The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system

J Pharm Pharmacol. 1996 Feb;48(2):136-46. doi: 10.1111/j.2042-7158.1996.tb07112.x.

Abstract

The presence of the blood-brain barrier (BBB), reduces the brain uptake of many drugs, peptides and other solutes from blood. Strategies for increasing the uptake of drugs and peptide-based drugs include; structural modifications to increase plasma half-life; improving passive penetration of the BBB by increasing the lipophilicity of the molecule; designing drugs which react with transporters present in the BBB; and reducing turnover and efflux from the central nervous system (CNS).

Publication types

  • Review

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Blood-Brain Barrier*
  • Brain / metabolism
  • Carrier Proteins / pharmacokinetics
  • Humans
  • Molecular Sequence Data
  • Molecular Structure
  • Peptides / chemistry
  • Peptides / pharmacokinetics*

Substances

  • Carrier Proteins
  • Peptides